April 24, 2024Open Access

Activity of Lutetium-177 Prostate-specific Membrane Antigen and Determinants of Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Cabazitaxel: The PACAP Study

Key Points

Key points are not available for this paper at this time.

Abstract

Both cabazitaxel and lutetium-177 prostate-specific membrane antigen (Lu-PSMA) improve survival in metastatic castration-resistant prostate cancer (mCRPC) after an androgen receptor pathway inhibitor and docetaxel, but there are limited data regarding Lu-PSMA activity after cabazitaxel.

Read Full Paperexternally

Bookmark

View Full Paper

Cite This Study

Flippot et al. (Wed,) studied this question.

synapsesocial.com/papers/68e6dc24b6db6435876584c0 https://doi.org/https://doi.org/10.1016/j.euo.2024.03.013

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries2021 · 112,541 citations
2Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer2004 · 5,725 citations
3[<sup>177</sup>Lu]Lu-PSMA-617 in PSMA-positive metastatic castration-resistant prostate cancer: Prior and concomitant treatment subgroup analyses of the VISION trial.2022 · 25 citations
4Updated recommendations of the International Society of Geriatric Oncology on prostate cancer management in older patients2019 · 230 citations
5PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial2022 · 267 citations

Bookmark

View Full Paper